Lillian L Siu, MD, FRCPC

Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine.

Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016.  She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 280 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology.

Developmental Therapeutics and Phase I Clinical Trials of Novel Agents

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute, which aims to expedite the access and evaluation of novel anti-cancer agents.

Related Links

Cancer Med. 2020 Mar 02;:
Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, Leighl N, Oza AM, Parsons JA, Hansen AR
Sci Rep. 2020 Jan 17;10(1):581
Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, Majewski J, Siu LL, Riazalhosseini Y, Graham DM
Genome Med. 2020 01 14;12(1):8
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL
Cancer. 2020 Apr 01;126(7):1550-1558
Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J
Curr Oncol. 2019 12;26(6):e717-e732
Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, McCready E, Sadikovic B, Siu LL, Bedard PL, Stockley TL
Radiother Oncol. 2020 Mar;144:13-22
Huang SH, O'Sullivan B, Su J, Bartlett E, Kim J, Waldron JN, Ringash J, de Almeida JR, Bratman S, Hansen A, Bayley A, Cho J, Giuliani M, Hope A, Hosni A, Spreafico A, Siu L, Chepeha D, Tong L, Xu W, Yu E
Curr Oncol. 2019 10;26(5):e618-e623
Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, Feilotter H, Hanna TP, Kamel-Reid S, Stockley TL, Siu LL, Bedard PL
Cancer Chemother Pharmacol. 2020 Feb;85(2):469-472
Kuehne N, Chen L, McDonald K, Wang L, Spreafico A, Hansen A, Razak ARA, Bedard PL, Siu LL, Shepshelovich D
Eur J Cancer. 2019 Dec;123:138-145
Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI
JAMA Oncol. 2019 Nov 07;:1-8
Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL

Pages


 

Professor of Medicine, University of Toronto
Staff Physician, Division of Medical Oncology and Hematology, Princess Margaret Hospital
Director, Phase I Program and Co-Director, Robert and Maggie Bras and Family Drug Development Program, Princess Margaret Hospital